Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/ TRANSCEND) Trials
- Author
- BÖHM, Michael1 ; BAUMHÄKEL, Magnus1 ; LISHENG LIU9 ; JANSKY, Petr10 ; YUSUF, Salim2 ; TEO, Koon2 ; SLEIGHT, Peter3 ; PROBSTFIELD, Jeffrey4 ; GAO, Peggy2 ; MANN, Johannes F5 ; DIAZ, Rafael6 ; DAGENAIS, Gilles R7 ; JENNINGS, Garry L. R8
[1] Department of Cardiology, University of the Saarland, Saarbrücken, Germany
[2] Population Health Research Institute (KT, P.G., S.Y.), McMaster University/Hamilton Health Sciences, Hamilton, Ontario, Canada
[3] University of Oxford, Oxford, United Kingdom
[4] University of Washington, School of Medicine, Seattle, Wash, United States
[5] Department of Nephrology, Hypertension and Rheumatology, Schwabing General Hospital, Munich, Germany
[6] Department of Cardiology, Instituto Cardiovascular de Rosario, Rosario, Argentina, United States
[7] Department of Medicine, University of Montreal, Montreal, Quebec, Canada
[8] Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia
[9] Chinese Hypertension League Institute, Beijing, China
[10] Department of Internal Medicine Motol University Hospital, Prague, Czech Republic
ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators - Source
Circulation (New York, N.Y.). 2010, Vol 121, Num 12, pp 1439-1446, 8 p ; ref : 28 ref
- CODEN
- CIRCAZ
- ISSN
- 0009-7322
- Scientific domain
- Cardiology, blood circulation, phlebology
- Publisher
- Lippincott Williams & Wilkins, Hagerstown, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Author keyword
- cardiovascular diseases drugs erectile dysfunction trials
- Keyword (fr)
- Antihypertenseur Homme Pathologie de l'appareil circulatoire Pathologie de l'érection Ramipril Telmisartan Maladie cardiovasculaire Récepteur AT1 de l'angiotensine II Angiotensine II Antagoniste angiotensine Dérivé de l'imidazole Dérivé du benzimidazole Enzyme Hormone peptide Hydrolases Inhibiteur angiotensin converting enzyme Inhibiteur enzyme Octapeptide Pathologie de l'appareil génital mâle Peptidases Peptidyl-dipeptidase A Peptidyl-dipeptidases Sartan dérivé Système renin angiotensine
- Keyword (en)
- Antihypertensive agent Human Cardiovascular disease Erection disorders Ramipril Telmisartan Cardiovascular disease Angiotensin II Angiotensin antagonist Imidazole derivatives Benzimidazole derivatives Enzyme Peptide hormone Hydrolases ACE inhibitor Enzyme inhibitor Octapeptide Male genital diseases Peptidases Peptidyl-dipeptidase A Peptidyl-dipeptidases Sartan derivatives Renin angiotensin system
- Keyword (es)
- Antihipertensivo Hombre Aparato circulatorio patología Erección patología Ramipril Telmisartán Cardiovascular enfermedad Angiotensina II Antagonista angiotensina Imidazol derivado Benzimidazol derivado Enzima Hormona péptido Hydrolases Inhibidor angiotensin converting enzyme Inhibidor enzima Octapéptido Aparato genital macho patología Peptidases Peptidyl-dipeptidase A Peptidyl-dipeptidases Sartan derivado Sistema renin angiotensina
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02F Cardiovascular system / 002B02F04 Vasodilator agents. Cerebral vasodilators
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B12 Cardiology. Vascular system / 002B12B Blood and lymphatic vessels / 002B12B03 Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
- Discipline
- Cardiology. Circulatory system Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 22571662
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:324:\"Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET\/ TRANSCEND) Trials\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Circulation (New York, N.Y.)\";s:9:\"\u0000*\u0000stitle\";s:24:\"Circulation (N. Y. N.Y.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"121\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1439\";s:8:\"\u0000*\u0000epage\";s:4:\"1446\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-7322\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"B\u00d6HM\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Michael\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:18:\"BAUMH\u00c4KEL, Magnus\";i:1;s:11:\"LISHENG LIU\";i:2;s:12:\"JANSKY, Petr\";i:3;s:12:\"YUSUF, Salim\";i:4;s:9:\"TEO, Koon\";i:5;s:14:\"SLEIGHT, Peter\";i:6;s:20:\"PROBSTFIELD, Jeffrey\";i:7;s:10:\"GAO, Peggy\";i:8;s:16:\"MANN, Johannes F\";i:9;s:12:\"DIAZ, Rafael\";i:10;s:18:\"DAGENAIS, Gilles R\";i:11;s:20:\"JENNINGS, Garry L. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIRCAZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:324:\"Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET\/ TRANSCEND) Trials\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:324:\"Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET\/ TRANSCEND) Trials\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Circulation (New York, N.Y.)\";s:9:\"\u0000*\u0000stitle\";s:24:\"Circulation (N. Y. N.Y.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"121\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1439\";s:8:\"\u0000*\u0000epage\";s:4:\"1446\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-7322\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"B\u00d6HM\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Michael\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:18:\"BAUMH\u00c4KEL, Magnus\";i:1;s:11:\"LISHENG LIU\";i:2;s:12:\"JANSKY, Petr\";i:3;s:12:\"YUSUF, Salim\";i:4;s:9:\"TEO, Koon\";i:5;s:14:\"SLEIGHT, Peter\";i:6;s:20:\"PROBSTFIELD, Jeffrey\";i:7;s:10:\"GAO, Peggy\";i:8;s:16:\"MANN, Johannes F\";i:9;s:12:\"DIAZ, Rafael\";i:10;s:18:\"DAGENAIS, Gilles R\";i:11;s:20:\"JENNINGS, Garry L. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIRCAZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:324:\"Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET\/ TRANSCEND) Trials\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:324:\"Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET\/ TRANSCEND) Trials\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Circulation (New York, N.Y.)\";s:9:\"\u0000*\u0000stitle\";s:24:\"Circulation (N. Y. N.Y.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"121\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1439\";s:8:\"\u0000*\u0000epage\";s:4:\"1446\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-7322\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"B\u00d6HM\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Michael\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:18:\"BAUMH\u00c4KEL, Magnus\";i:1;s:11:\"LISHENG LIU\";i:2;s:12:\"JANSKY, Petr\";i:3;s:12:\"YUSUF, Salim\";i:4;s:9:\"TEO, Koon\";i:5;s:14:\"SLEIGHT, Peter\";i:6;s:20:\"PROBSTFIELD, Jeffrey\";i:7;s:10:\"GAO, Peggy\";i:8;s:16:\"MANN, Johannes F\";i:9;s:12:\"DIAZ, Rafael\";i:10;s:18:\"DAGENAIS, Gilles R\";i:11;s:20:\"JENNINGS, Garry L. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIRCAZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:324:\"Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET\/ TRANSCEND) Trials\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:324:\"Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET\/ TRANSCEND) Trials\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Circulation (New York, N.Y.)\";s:9:\"\u0000*\u0000stitle\";s:24:\"Circulation (N. Y. N.Y.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"121\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1439\";s:8:\"\u0000*\u0000epage\";s:4:\"1446\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-7322\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"B\u00d6HM\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Michael\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:18:\"BAUMH\u00c4KEL, Magnus\";i:1;s:11:\"LISHENG LIU\";i:2;s:12:\"JANSKY, Petr\";i:3;s:12:\"YUSUF, Salim\";i:4;s:9:\"TEO, Koon\";i:5;s:14:\"SLEIGHT, Peter\";i:6;s:20:\"PROBSTFIELD, Jeffrey\";i:7;s:10:\"GAO, Peggy\";i:8;s:16:\"MANN, Johannes F\";i:9;s:12:\"DIAZ, Rafael\";i:10;s:18:\"DAGENAIS, Gilles R\";i:11;s:20:\"JENNINGS, Garry L. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIRCAZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:324:\"Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET\/ TRANSCEND) Trials\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:324:\"Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET\/ TRANSCEND) Trials\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Circulation (New York, N.Y.)\";s:9:\"\u0000*\u0000stitle\";s:24:\"Circulation (N. Y. N.Y.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"121\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1439\";s:8:\"\u0000*\u0000epage\";s:4:\"1446\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-7322\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"B\u00d6HM\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Michael\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:18:\"BAUMH\u00c4KEL, Magnus\";i:1;s:11:\"LISHENG LIU\";i:2;s:12:\"JANSKY, Petr\";i:3;s:12:\"YUSUF, Salim\";i:4;s:9:\"TEO, Koon\";i:5;s:14:\"SLEIGHT, Peter\";i:6;s:20:\"PROBSTFIELD, Jeffrey\";i:7;s:10:\"GAO, Peggy\";i:8;s:16:\"MANN, Johannes F\";i:9;s:12:\"DIAZ, Rafael\";i:10;s:18:\"DAGENAIS, Gilles R\";i:11;s:20:\"JENNINGS, Garry L. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIRCAZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:324:\"Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET\/ TRANSCEND) Trials\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
